Eplerenone API

Name	Eplerenone
Chinese name	依普利酮
Cas Number	107724-20-9
Source	Switzerland
Qualifications	USDMF/-/-/-/-

Eplerenone (Inspra) is a newer generation of selective aldosterone inhibitors, originally developed by Pharmacia (Pfizer) and approved in the United States in October 2002 for the treatment of hypertension and congestive heart failure. Aldosterone has a wide range of effects on the cardiovascular system. It can not only affect the pathophysiological changes of the cardiovascular system through its effects on water and sodium retention and plasma low potassium and low magnesium, but also cause fibrosis of the heart and blood vessels, abnormal endothelial function, and vascular damage. Many cardiovascular diseases. Spironolactone, a commonly used aldosterone receptor antagonist in China, has a significant protective effect on the cardiovascular system, but its sex hormone-related side effects limit its application. Eplerenone has a stronger antagonistic effect on aldosterone than spironolactone, and has very low affinity for androgen and progesterone receptors, with low adverse reactions. It has a definite effect on the treatment of hypertension, heart failure and myocardial infarction, with fewer adverse reactions and tolerable It has good properties and is a good alternative medicine for spironolactone. As a newer generation of selective aldosterone receptor antagonist, eplerenone has opened up a new path for the treatment of cardiovascular diseases and has a good clinical prospect.

Hot Tags: eplerenone api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pazopanib Hydrochloride Pazopanib API, Gabapentin API, Pleasant API, Troxagliptin Succinate API, Lapatinib Ditosylate API, Canagliflozin API

• Previous: Gestodene API
• Next: Diquafoxol API